$-0.08 EPS Expected for TrovaGene, Inc. (TROV) as of May, 9

April 17, 2018 - By Andrea Pope

TrovaGene, Inc. (NASDAQ:TROV) Corporate Logo
During Q4 2017 the big money sentiment decreased to 0.53. That’s change of 0.32, from 2017Q3’s 0.85. 7 investors sold all, 10 reduced holdings as TrovaGene, Inc. ratio worsened. 6 rose holdings while 3 funds acquired holdings. Funds hold 2.44 million shares thus 51.68% less from 2017Q3’s 5.05 million shares.
Virtu Ltd Limited Liability Company holds 71,678 shs. Northwestern Mutual Wealth Mgmt holds 3,400 shs. North Carolina-based Natl Bank Of America De has invested 0% in TrovaGene, Inc. (NASDAQ:TROV). Bank Of New York Mellon holds 56,488 shs or 0% of its capital. Geode Capital Mngmt has invested 0% in TrovaGene, Inc. (NASDAQ:TROV). Florida-based Raymond James has invested 0% in TrovaGene, Inc. (NASDAQ:TROV). Millennium Mgmt Limited Liability Com, a New York-based fund reported 111,354 shs. Northern Trust Corp owns 0% invested in TrovaGene, Inc. (NASDAQ:TROV) for 56,052 shs. Cwm Ltd Liability Co holds 0% of its capital in TrovaGene, Inc. (NASDAQ:TROV) for 1,000 shs. Bancorporation Of Montreal Can has 0% invested in TrovaGene, Inc. (NASDAQ:TROV) for 22,500 shs. Jpmorgan Chase & reported 811 shs. Bnp Paribas Arbitrage reported 0% in TrovaGene, Inc. (NASDAQ:TROV). Moreover, Vanguard Group Inc has 0% invested in TrovaGene, Inc. (NASDAQ:TROV) for 774,614 shs. Barclays Public Ltd Limited Liability Company holds 25,000 shs or 0% of its capital. 5,433 are held by Meeder Asset Management.

TrovaGene, Inc. (NASDAQ:TROV)’s quarterly earnings will be announced On May, 9., as reported by Faxor. Analysts predict $-0.08 earnings per share. That’s $0.18 up or 69.23 % from 2017’s earnings of $-0.26. Wall Street sees 33.33 % negative EPS growth as of May, 9. TROV reached $0.3649 on during the last trading session after $0.0028 change.TrovaGene, Inc. is downtrending after having declined 66.35% since April 17, 2017. TROV has 3.41 million volume or 68.24% up from normal. The stock underperformed the S&P 500 by 77.90%.

TrovaGene, Inc. (NASDAQ:TROV) Ratings Coverage

In total 2 analysts cover TrovaGene (NASDAQ:TROV). “Buy” rating has 1, “Sell” are 0, while 1 are “Hold”. 50% are bullish. 3 are the (NASDAQ:TROV)’s analyst reports since November 10, 2017 according to StockzIntelligence Inc. On Thursday, December 21 the firm has “Buy” rating given by H.C. Wainwright. On Tuesday, March 6 H.C. Wainwright maintained the shares of TROV in report with “Buy” rating. In Friday, November 10 report Maxim Group downgraded the stock to “Hold” rating.

Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring technology in tumor genomics.The firm is worth $20.18 million. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.Last it reported negative earnings. The PCM-075 is an orally bioavailable, which has explored in preclinical antitumor activity as a single agent and in synergy combinations with approximately 10 different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib, a development stage FLT3 inhibitor, and Velcade (bortezomib) in acute myeloid leukemia (AML), metastatic castration-resistant prostate cancer, and other liquid and solid tumor cancers.

TrovaGene, Inc. (NASDAQ:TROV) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.